AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35765137 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-clinician agreement
Number of subjects: 98
Study 35765137 — intervention group
Group type: EXPERIMENTAL
Intervention: Topographic pain frequency maps
Number of subjects: 98
Study 33389189 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg 2 hours before surgery
Number of subjects: 60
Study 33389189 — intervention group
Group type: COMPARATOR
Intervention: TAP block with 60 mL 0.25% levobupivacaine after general anesthesia
Number of subjects: 60
Study 33389189 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg 2 hours before surgery and 50 mg rectal diclofenac sodium on recovery from general anesthesia
Number of subjects: 60
Study 35869503 — intervention group
Group type: EXPERIMENTAL
Intervention: automated, theory‐informed text messages daily for 12 months plus endowment incentives linked to verified weight loss targets at 3, 6 and 12 months
Number of subjects: 585
Study 35869503 — intervention group
Group type: EXPERIMENTAL
Intervention: the same text messages and weight loss assessment protocol
Number of subjects: 585
Study 35869503 — intervention group
Group type: COMPARATOR
Intervention: 12 month waiting list, then text messages for 3 months
Number of subjects: 585
Study 34175558 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% HRR exercise
Number of subjects: 83
Study 34175558 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% HRR exercise
Number of subjects: 83
Study 34175558 — intervention group
Group type: EXPERIMENTAL
Intervention: 70% HRR exercise
Number of subjects: 83
Study 34016024 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-load/high-repetition resistance training (LL/HR)
Number of subjects: 31
Study 34016024 — intervention group
Group type: EXPERIMENTAL
Intervention: High-load/low-repetition resistance training (HL/LR)
Number of subjects: 31
Study 34656640 — intervention group
Group type: EXPERIMENTAL
Intervention: BIA-guided volume management
Number of subjects: 65
Study 34656640 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 65
Study 34656640 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol 50,000 U weekly for 8 weeks followed by 10,000 U weekly for 44 weeks
Number of subjects: 65
Study 34656640 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 34444963 — intervention group
Group type: EXPERIMENTAL
Intervention: 688 mg/day palmiteolate (omega-7 fatty acid supplementation)
Number of subjects: 56
Study 34444963 — intervention group
Group type: COMPARATOR
Intervention: Medium-chain triglycerides (placebo)
Number of subjects: 56
Study 35104737 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg donepezil hydrochloride (test formulation)
Number of subjects: 0
Study 35104737 — intervention group
Group type: COMPARATOR
Intervention: 10 mg donepezil hydrochloride (reference formulation)
Number of subjects: 0
Study 33218514 — intervention group
Group type: EXPERIMENTAL
Intervention: CV4 technique
Number of subjects: 90
Study 33218514 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study 33218514 — intervention group
Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 90
Study 35001501 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilpivirine (RPV) 25 mg tablet once daily, switched from Efavirenz (EFV) plus two NRTIs for ≥3 months
Number of subjects: 102
Study 35001501 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilpivirine (RPV) 25 mg tablet once daily
Number of subjects: 102
Study 34357729 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive self-ligation braces, Pitts Broad, and early short elastics
Number of subjects: 46
Study 34357729 — intervention group
Group type: COMPARATOR
Intervention: Ligature braces and archwires Orthos
Number of subjects: 46
Study 34913149 — intervention group
Group type: EXPERIMENTAL
Intervention: Jiuwei Zhuhuang Powder (JWZH) 1 to 1.5 g, twice to thrice daily for 5 days
Number of subjects: 142
Study 34913149 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (Pediatric Paracetamol, Artificial Cow‐bezoar and Chlorphenamine Maleate Granules, 0.25 to 1 g, thrice daily for 5 days)
Number of subjects: 142
Study 34913149 — intervention group
Group type: EXPERIMENTAL
Intervention: Jiuwei Zhuhuang Powder (JWZH)
Number of subjects: 142
Study 34913149 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (Pediatric Paracetamol, Artificial Cow‐bezoar and Chlorphenamine Maleate Granules)
Number of subjects: 142
Study 32600260 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard syphilis self-testing arm
Number of subjects: 444
Study 32600260 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-testing arm enhanced with crowdsourcing and a lottery-based incentive
Number of subjects: 444
Study 32600260 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control)
Number of subjects: 444
Study 34688773 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 34
Study 32271690 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic radical cystectomy
Number of subjects: 302
Study 32271690 — intervention group
Group type: COMPARATOR
Intervention: Open radical cystectomy
Number of subjects: 302
Study 32271690 — intervention group
Group type: EXPERIMENTAL
Intervention: Continent diversion
Number of subjects: 302
Study 32271690 — intervention group
Group type: COMPARATOR
Intervention: Noncontinent diversion
Number of subjects: 302
Study 616659783 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled diet plan given by a nutritionist
Number of subjects: 244
Study 616659783 — intervention group
Group type: COMPARATOR
Intervention: Free diet
Number of subjects: 244
Study 34553256 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep-learning model for identifying fresh VCFs from digital radiography (DR)
Number of subjects: 1099
Study 34553256 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral views of DR
Number of subjects: 1099
Study 34553256 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade 3 VCF subgroup
Number of subjects: 1099
Study 34553256 — intervention group
Group type: EXPERIMENTAL
Intervention: Crush-type VCF subgroup
Number of subjects: 1099
Study 32470089 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard cash incentive (US$4)
Number of subjects: 130
Study 32470089 — intervention group
Group type: EXPERIMENTAL
Intervention: Commitment contract (low- or high-value deposit returned with interest upon retesting)
Number of subjects: 130
Study 32470089 — intervention group
Group type: COMPARATOR
Intervention: No incentive
Number of subjects: 130
Study 36064428 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Assessment Protocol (GAP)
Number of subjects: 13
Study 32459670 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiotaping and Lymphatic drainage Group
Number of subjects: 99
Study 32459670 — intervention group
Group type: COMPARATOR
Intervention: Lymphatic drainage Group
Number of subjects: 99
Study 32459670 — intervention group
Group type: COMPARATOR
Intervention: Kinesiotaping Group
Number of subjects: 99
Study 34612802 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical meditation and imagery (CMI) intervention
Number of subjects: 24
Study 34612802 — intervention group
Group type: COMPARATOR
Intervention: Control group (education on health and function after SCI)
Number of subjects: 24
Study 33813585 — intervention group
Group type: EXPERIMENTAL
Intervention: High-concentration phospholipid eye spray (Tears Again)
Number of subjects: 30
Study 33813585 — intervention group
Group type: COMPARATOR
Intervention: Low-concentration phospholipid eye spray (Ocuvers)
Number of subjects: 30
Study 35629004 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-week serious game-based auditory training (AT) program
Number of subjects: 30
Study 35629004 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 34039773 — intervention group
Group type: EXPERIMENTAL
Intervention: Lègong dance training (DG)
Number of subjects: 40
Study 34039773 — intervention group
Group type: COMPARATOR
Intervention: Aerobic training (AG)
Number of subjects: 40
Study 36089810 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg once daily
Number of subjects: 24
Study 36089810 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg once daily
Number of subjects: 24
Study 36089810 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin + Losartan
Number of subjects: 24
Study 36089810 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 24
Study 36089810 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 24
Study 36089810 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 34418224 — intervention group
Group type: EXPERIMENTAL
Intervention: Anonymous participation
Number of subjects: 0
Study 34418224 — intervention group
Group type: COMPARATOR
Intervention: Confidential participation
Number of subjects: 0
Study 34418224 — intervention group
Group type: COMPARATOR
Intervention: Confidential participation with consent for collection of register data
Number of subjects: 0
Study 32739652 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel monotherapy for 9 months
Number of subjects: 7700
Study 32739652 — intervention group
Group type: COMPARATOR
Intervention: Aspirin plus clopidogrel for 9 months followed by aspirin monotherapy for 3 months
Number of subjects: 7700
Study 34044526 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil at 0.5 mg/mL combined with triamcinolone
Number of subjects: 29
Study 34044526 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil at 5.0 mg/mL combined with triamcinolone
Number of subjects: 29
Study 34044526 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil at 12.5 mg/mL combined with triamcinolone
Number of subjects: 29
Study 34044526 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 29
Study 33121503 — intervention group
Group type: EXPERIMENTAL
Intervention: FTC‐TDF or FTC‐TAF (over 1 or 2 days, with final dose given either 6 or 20 hours prior to surgery)
Number of subjects: 144
Study 33121503 — intervention group
Group type: COMPARATOR
Intervention: No PrEP prior to surgery
Number of subjects: 144
Study 33852247 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Number of subjects: 0
Study 33259621 — intervention group
Group type: EXPERIMENTAL
Intervention: Multistrategic, community-wide interventions using social marketing techniques and network intervention (e.g., word of mouth) over 5 years
Number of subjects: 0
Study 33259621 — intervention group
Group type: COMPARATOR
Intervention: Previous studies with interventions lasting 1 to 3 years
Number of subjects: 0
Study 35556389 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-week lithium treatment (40 mmol/kg/food)
Number of subjects: 9
Study 35556389 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week lithium treatment (40 mmol/kg/food)
Number of subjects: 9
Study 35556389 — intervention group
Group type: COMPARATOR
Intervention: Placebo group from previous trial
Number of subjects: 9
Study 33007353 — intervention group
Group type: EXPERIMENTAL
Intervention: Patiromer (starting doses ranged from 8.4 to 33.6 g/day)
Number of subjects: 653
Study 33007353 — intervention group
Group type: EXPERIMENTAL
Intervention: Patiromer (safety outcomes)
Number of subjects: 653
Study 33949680 — intervention group
Group type: EXPERIMENTAL
Intervention: Written communication via leaflet with visual aids (L-VA)
Number of subjects: 99
Study 33949680 — intervention group
Group type: EXPERIMENTAL
Intervention: Written communication via leaflet with no visual aids (L-NVA)
Number of subjects: 99
Study 33949680 — intervention group
Group type: COMPARATOR
Intervention: Only verbal communication with no leaflet (NL)
Number of subjects: 99
Study 33949680 — intervention group
Group type: EXPERIMENTAL
Intervention: Health belief model constructs
Number of subjects: 99
Study 34600178 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-load plyometric running intervention
Number of subjects: 31
Study 34600178 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 31
Study 32873311 — intervention group
Group type: EXPERIMENTAL
Intervention: Women living with HIV
Number of subjects: 1693
Study 32873311 — intervention group
Group type: COMPARATOR
Intervention: Women not living with HIV
Number of subjects: 1693
Study 32873311 — intervention group
Group type: EXPERIMENTAL
Intervention: Women living with HIV (currently breastfeeding)
Number of subjects: 1693
Study 32873311 — intervention group
Group type: COMPARATOR
Intervention: Women not living with HIV (currently breastfeeding)
Number of subjects: 1693
Study 35143607 — intervention group
Group type: EXPERIMENTAL
Intervention: REST intervention (occupational therapist‐led cognitive‐behavioral therapy for insomnia)
Number of subjects: 15
Study 32963087 — intervention group
Group type: EXPERIMENTAL
Intervention: Videolaryngoscopy with shared airway view
Number of subjects: 36
Study 32963087 — intervention group
Group type: COMPARATOR
Intervention: Videolaryngoscopy with covered screen
Number of subjects: 36
Study 32963087 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled environment and calm guidance
Number of subjects: 36
Study 32963087 — intervention group
Group type: EXPERIMENTAL
Intervention: Intubations in stressful situations (delivery room, unstable infants, large audiences, parental presence)
Number of subjects: 36
Study 35377261 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation (VNS) paired with rehabilitation
Number of subjects: 100
Study 35377261 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation alone
Number of subjects: 100
Study 34211988 — intervention group
Group type: EXPERIMENTAL
Intervention: 308-nm excimer lamp monotherapy
Number of subjects: 30
Study 34211988 — intervention group
Group type: COMPARATOR
Intervention: Combination of 308-nm excimer lamp and 10% liquor carbonis detergens
Number of subjects: 30
Study 35654818 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 240
Study 35654818 — intervention group
Group type: COMPARATOR
Intervention: Control (no colchicine)
Number of subjects: 240
Study 35077306 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Group (HG)
Number of subjects: 65
Study 35077306 — intervention group
Group type: EXPERIMENTAL
Intervention: Training Group (TG)
Number of subjects: 65
Study 35077306 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 65
Study 84116008 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial hospitalization
Number of subjects: 0
Study 84116008 — intervention group
Group type: COMPARATOR
Intervention: Inpatient hospitalization
Number of subjects: 0
Study 36162143 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional weightbearing (WB) quadriceps strengthening exercise
Number of subjects: 67
Study 36162143 — intervention group
Group type: COMPARATOR
Intervention: Non-weightbearing (NWB) quadriceps strengthening exercise
Number of subjects: 67
Study 33414533 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic mycophenolate mofetil (MMF) 1 g orally twice daily for the first 6 months, then 1 g daily for the next 6 months, plus corticosteroids
Number of subjects: 63
Study 33414533 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.03% tacrolimus four times a day for 12 months, plus corticosteroids
Number of subjects: 63
Study 33414533 — intervention group
Group type: COMPARATOR
Intervention: Systemic mycophenolate mofetil (MMF)
Number of subjects: 63
Study 33414533 — intervention group
Group type: COMPARATOR
Intervention: Topical 0.03% tacrolimus
Number of subjects: 63
Study 35543937 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with regular treatment and swallowing function training
Number of subjects: 60
Study 35543937 — intervention group
Group type: COMPARATOR
Intervention: Control group (regular treatment and swallowing function training only)
Number of subjects: 60
Study 32698033 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical antibiotic ointment
Number of subjects: 401
Study 32698033 — intervention group
Group type: COMPARATOR
Intervention: Placebo (mineral oil and petrolatum‐based) ointment
Number of subjects: 401
Study 36397221 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with Qingfei Qutan decoction
Number of subjects: 99
Study 36397221 — intervention group
Group type: EXPERIMENTAL
Intervention: Qingfei Qutan decoction
Number of subjects: 99
Study 36397221 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 99
Study 32293044 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryolipolysis plus low-calorie diet
Number of subjects: 60
Study 32293044 — intervention group
Group type: COMPARATOR
Intervention: Low-calorie diet only
Number of subjects: 60
Study 36402275 — intervention group
Group type: EXPERIMENTAL
Intervention: OUD‐SDM system
Number of subjects: 92
Study 34002252 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly subcutaneous injection of teriparatide 56.5 μg for 72 weeks
Number of subjects: 1011
Study 34002252 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy with alendronate for 120 weeks
Number of subjects: 1011
Study 32798570 — intervention group
Group type: EXPERIMENTAL
Intervention: HL‐RE
Number of subjects: 29
Study 32798570 — intervention group
Group type: EXPERIMENTAL
Intervention: cBFR‐RE
Number of subjects: 29
Study 32798570 — intervention group
Group type: EXPERIMENTAL
Intervention: LL‐RE
Number of subjects: 29
Study 35974359 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentle heat application with hot water bottles at any sign of illness and onset of fever.
Number of subjects: 24
Study 35974359 — intervention group
Group type: COMPARATOR
Intervention: Standard antipyretic treatment from the participating hospital.
Number of subjects: 24
Study 32435929 — intervention group
Group type: EXPERIMENTAL
Intervention: ESR eGUIDE
Number of subjects: 40
Study 32435929 — intervention group
Group type: COMPARATOR
Intervention: Control (no ESR eGUIDE)
Number of subjects: 40
Study 33221636 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized intervention group (SIG) - brief perioperative smoking cessation intervention with nicotine patch therapy for 8 weeks
Number of subjects: 56
Study 33221636 — intervention group
Group type: COMPARATOR
Intervention: Usual care group (UCG) - standard care without the intervention
Number of subjects: 56
Study 35341647 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose (SD, 5x10^10 viral particles)
Number of subjects: 422
Study 35341647 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose (LD, 2.5x10^10 viral particles)
Number of subjects: 422
Study 33780274 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpelisib 300 mg daily plus fulvestrant 500 mg
Number of subjects: 341
Study 33780274 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus fulvestrant 500 mg
Number of subjects: 341
Study 33780274 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpelisib
Number of subjects: 341
Study 33780274 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 341
Study 32053243 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower BMI
Number of subjects: 224
Study 32053243 — intervention group
Group type: COMPARATOR
Intervention: Higher BMI
Number of subjects: 224
Study 32053243 — intervention group
Group type: EXPERIMENTAL
Intervention: Female participants
Number of subjects: 224
Study 32053243 — intervention group
Group type: EXPERIMENTAL
Intervention: Male participants
Number of subjects: 224
Study 32053243 — intervention group
Group type: EXPERIMENTAL
Intervention: Tall participants
Number of subjects: 224
Study 34603765 — intervention group
Group type: COMPARATOR
Intervention: SAA (Serum Amyloid A) levels
Number of subjects: 75
Study 34603765 — intervention group
Group type: COMPARATOR
Intervention: ICAM-1 levels
Number of subjects: 75
Study 34603765 — intervention group
Group type: COMPARATOR
Intervention: VCAM-1 levels
Number of subjects: 75
Study 34603765 — intervention group
Group type: COMPARATOR
Intervention: sCD27 levels
Number of subjects: 75
Study 32147925 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-soluble CBD powder (30 mg)
Number of subjects: 10
Study 32147925 — intervention group
Group type: COMPARATOR
Intervention: Lipid-soluble CBD powder (30 mg)
Number of subjects: 10
Study 32147925 — intervention group
Group type: EXPERIMENTAL
Intervention: CBD exposure (both formulations)
Number of subjects: 10
Study 35579901 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 0
Study 33639578 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingroup associated with high status
Number of subjects: 0
Study 33639578 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingroup associated with low status
Number of subjects: 0
Study 33639578 — intervention group
Group type: COMPARATOR
Intervention: Outgroup associated with high status
Number of subjects: 0
Study 33639578 — intervention group
Group type: COMPARATOR
Intervention: Outgroup associated with low status
Number of subjects: 0
Study 32048356 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG with transseptal and transepicardial implantation of CD133+
Number of subjects: 30
Study 32048356 — intervention group
Group type: COMPARATOR
Intervention: CABG alone
Number of subjects: 30
Study 36028073 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIE-S (Single session of high-intensity interval exercise)
Number of subjects: 20
Study 36028073 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIE-D (Two sessions of high-intensity interval exercise 3 hours apart)
Number of subjects: 20
Study 34060144 — intervention group
Group type: EXPERIMENTAL
Intervention: Low straw (LS, starter feed containing 10% dry matter basis straw; n=11)
Number of subjects: 44
Study 34060144 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium straw (MS, starter feed containing 15% dry matter basis straw; n=11)
Number of subjects: 44
Study 34060144 — intervention group
Group type: EXPERIMENTAL
Intervention: High straw (HS, starter feed containing 20% dry matter basis straw; n=11)
Number of subjects: 44
Study 34060144 — intervention group
Group type: COMPARATOR
Intervention: Control (CON, starter without straw; n=11)
Number of subjects: 44
Study 32652544 — intervention group
Group type: EXPERIMENTAL
Intervention: CZP 200 mg Q2W
Number of subjects: 361
Study 32652544 — intervention group
Group type: EXPERIMENTAL
Intervention: CZP 400 mg Q2W
Number of subjects: 361
Study 32652544 — intervention group
Group type: COMPARATOR
Intervention: Placebo (followed by CZP 400 mg Q2W escape arm)
Number of subjects: 361
Study 36432409 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber supplement
Number of subjects: 131
Study 36432409 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplement
Number of subjects: 131